iNtRON Biotechnology saw no growth in patent filings in April and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of iNtRON Biotechnology’s patent filings and grants. Buy the databook here.
iNtRON Biotechnology has been focused on protecting inventions in European Patent Office(EPO) with four publications in Q2 2024
The World Intellectual Property Organization(WIPO), European Patent Office(EPO), Canada(CA), and United States(US) patent Office are among the top ten patent offices where iNtRON Biotechnology is filings its patents. Among the top granted patent authorities, iNtRON Biotechnology has 50% of its grants in Canada(CA) and 50% in United States(US).
Roche could be the strongest competitor for iNtRON Biotechnology
Patents related to health & wellness and climate change lead iNtRON Biotechnology's portfolio
iNtRON Biotechnology has the highest number of patents in health & wellness followed by, climate change and precision agriculture.
Biocides related patents lead iNtRON Biotechnology portfolio followed by agricultural technology & crop science, and disinfectants and sanitizers
iNtRON Biotechnology has highest number of patents in biocides followed by agricultural technology & crop science, disinfectants and sanitizers, food, and agriculture.
For comprehensive analysis of iNtRON Biotechnology's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.